SCHEMBL3449093

SCHEMBL3449093

COc1cc(Nc2ncc(-c3cnc(OC)c(C(=O)NOCCN4CCOCC4)c3)c(-n3ccc(C(F)(F)F)n3)n2)cc(OC)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.42
FGFR1 P11362 1/20 0.40
CSF1R P07333 3/20 0.39
DAPK1 P53355 3/20 0.39
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
KCNH2 Q12809 1/20 0.38
PDE4B Q07343 1/20 0.38
JAK2 O60674 1/20 0.38
JAK3 P52333 1/20 0.38
PTK2 Q05397 1/20 0.38
RAF1 P04049 3/20 0.38
BRAF P15056 3/20 0.38
TYRO3 Q06418 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3449793 0.89 TYRO3 (0.37) SYKDAPK1HDAC3HDAC1HDAC2
SCHEMBL3451603 0.88 PTGER4 (0.41) SYKFGFR1CSF1RDAPK1KCNH2
SCHEMBL3375345 0.86 TYRO3 (0.39) SYKDAPK1HDAC3HDAC1HDAC2
SCHEMBL3449795 0.86 TYRO3 (0.40) SYKCSF1RDAPK1HDAC3HDAC1
SCHEMBL3451240 0.84 PTK2 (0.41) DAPK1HDAC3HDAC1HDAC2HDAC6
SCHEMBL3376690 0.82 TYRO3 (0.40) SYKDAPK1HDAC3HDAC1HDAC2
SCHEMBL3375491 0.82 SYK (0.41) SYKDAPK1HDAC3HDAC1HDAC2
SCHEMBL3375703 0.82 SYK (0.40) SYKHDAC3HDAC1HDAC2HDAC6
SCHEMBL3449383 0.81 SYK (0.43) SYKFGFR1CSF1RDAPK1PDE4B
SCHEMBL3448548 0.81 TYRO3 (0.37) DAPK1HDAC3HDAC1HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD SYK 804/4885FGFR1 3917/4885CSF1R 3603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.